Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
Latest Information Update: 14 Dec 2023
Price :
$35 *
At a glance
- Drugs Benmelstobart (Primary) ; Carboplatin (Primary) ; Etoposide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 24 Oct 2023 Results assessing Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer presented at the 48th European Society for Medical Oncology Congress
- 12 May 2023 Treatment section is updated to replace cisplatin with carboplatin. Adjuvant and neoadjuvant treatment is removed and only induction and maintenance therapies are retained in treatment. Timeline for primary end point is increased from 4 months to 16 months.
- 25 Jan 2021 Status changed from not yet recruiting to recruiting.